Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by Ally Bridge Group NY LLC

Ally Bridge Group NY LLC lessened its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 39.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 141,710 shares of the company's stock after selling 93,146 shares during the quarter. Enliven Therapeutics makes up about 2.7% of Ally Bridge Group NY LLC's portfolio, making the stock its 17th biggest position. Ally Bridge Group NY LLC owned approximately 0.29% of Enliven Therapeutics worth $3,188,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Tower Research Capital LLC TRC boosted its position in shares of Enliven Therapeutics by 230.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after purchasing an additional 1,114 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Enliven Therapeutics during the fourth quarter worth about $97,000. ExodusPoint Capital Management LP acquired a new position in shares of Enliven Therapeutics during the fourth quarter valued at about $200,000. China Universal Asset Management Co. Ltd. raised its position in shares of Enliven Therapeutics by 14.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company's stock valued at $233,000 after purchasing an additional 1,275 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in Enliven Therapeutics by 17.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,627 shares of the company's stock worth $307,000 after purchasing an additional 1,980 shares in the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Enliven Therapeutics news, CEO Samuel Kintz sold 12,500 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $20.83, for a total transaction of $260,375.00. Following the transaction, the chief executive officer now directly owns 990,392 shares of the company's stock, valued at $20,629,865.36. This trade represents a 1.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Anish Patel sold 6,667 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $21.93, for a total value of $146,207.31. Following the completion of the transaction, the chief operating officer now owns 329,977 shares in the company, valued at approximately $7,236,395.61. This trade represents a 1.98 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 76,111 shares of company stock valued at $1,516,746. Company insiders own 29.20% of the company's stock.

Enliven Therapeutics Stock Down 7.2 %

Shares of Enliven Therapeutics stock traded down $1.42 on Wednesday, reaching $18.28. 42,307 shares of the stock were exchanged, compared to its average volume of 260,208. Enliven Therapeutics, Inc. has a twelve month low of $13.30 and a twelve month high of $30.03. The business has a 50 day moving average price of $19.16 and a two-hundred day moving average price of $22.26. The firm has a market capitalization of $896.68 million, a price-to-earnings ratio of -9.63 and a beta of 1.07.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. Research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright raised their price target on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a report on Friday, March 21st.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.